- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 57
Gravie gravitates to $75m series E round
Axa Venture Partners has returned to take part in the personalised health insurance service’s latest round, a year after it raised $28m in series D funding.
Mar 11, 2022Colossal Biosciences engineers $60m series A
Animoca Brands and Untamed Planet have stepped out of the crypto and gaming sphere to invest in a genetic engineering startup looking to bring back the woolly mammoth.
Mar 11, 2022Deals: March 10, 2022
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Mar 10, 2022TRexBio tracks corporates for $85m series A close
Eli Lilly, Johnson & Johnson Innovation – JJDC, Pfizer Ventures and Alexandria Venture Investments all returned for the $26m second tranche of the immunobiology therapy developer’s series A round.
Mar 10, 2022Daily Deal Round Up: March 9, 2022
JPMorgan Chase and Salesforce Ventures took part in financial services provider Propel's $50m series B round while prayer app developer Glorify closed its second $40m round in three months.
Mar 9, 2022DNAnexus draws $200m in funding
Returning investor GV returned for a round which hiked the clinical data software provider's overall funding to over $470m.
Mar 9, 2022Sherlock Biosciences detects $80m in series B round
Illumina Ventures was among the investors in the Baidu-backed diagnostics tool developer’s latest round, boosting its overall funding to $111m.
Mar 9, 2022Daily Deal Round Up: March 8, 2022
Banking software provider Zeta netted $30m from investors including Mastercard at a $1.5bn valuation while drug development services provider Staq Pharma closed its series C round.
Mar 8, 2022AN2 Therapeutics examines IPO possibilities
The Brii Biosciences-backed lung diease drug developer will use the proceeds from the offering to advance its epetraborole drug candidate and expand into Japan.
Mar 8, 2022Microbiotica digests series B funding
The microbiome therapeutics developer, which was spun out of Wellcome Sanger Institute, completed a $66.6m round co-led by Tencent
Mar 8, 2022About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


